Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
etodolac + propranolol + sorafenib
- Development stage
- Unknown
- Lead developer
- Vicus Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A fixed combination therapy consisting of **etodolac** (a nonsteroidal anti-inflammatory drug, NSAID and COX-2 inhibitor), **propranolol** (a non-selective beta-adrenergic receptor antagonist, beta-blocker), and **sorafenib** (a multikinase inhibitor targeting angiogenesis and tumor growth signaling pathways). This combination is designed to synergistically suppress tumor-promoting inflammation, stress adrenergic signaling, and direct tumor growth pathways in cancer. Clinical studies show that this regimen may improve overall survival in advanced hepatocellular carcinoma and stabilize weight loss, with a reduction in certain toxicities. **VT-122** is the proprietary chronodosed combination of etodolac + propranolol; when coadministered with sorafenib, the therapy is under clinical development primarily in oncology, especially for hepatocellular carcinoma[3][5][7].
- Brand names
- VT-122 + Nexavar
- Other names
- etodolac + propranolol + sorafenib
02
Targets
ADRB1 (β1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)FLT3 (Fms related receptor tyrosine kinase 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRB (Platelet-derived growth factor receptor beta)RAF1 (c-Raf-1 (Y340D/Y341D))RET (Rearranged during transfection receptor tyrosine kinase)TRPA1 (Transient receptor potential cation channel subfamily A member 1)VEGFR (VEGFR family)
Beyond the preview
Go deeper on etodolac + propranolol + sorafenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on etodolac + propranolol + sorafenib.